Leading the Way in Life Science Technologies

GEN Exclusives

More »

Best of the Web

More »
Jun 01, 2006 (Vol. 26, No. 11)


  • Outstanding breadth
  • None
A few years ago, digital books were all the rage. There was talk that digital books would replace traditional publishing, and while they have made inroads in many places, the print publishing industry is still in pretty good shape. What has happened in the interim, however, has been enormous expansion of digital offerings and the DigitalBookIndex is a great place to stay on top of it. Access to the site requires free registration and you can opt out of receiving additional info. After you’re in, you can search the lists by author, title, keyword, subject, or publisher. Books are available in PDF, HTML, and a variety of formats. There are free versions (out of copyright) and books for sale through the site. Perhaps I’m a purist, but if I’m going to pay for a book, I prefer to have it in printed form. Still, an awesome set of titles and a very well-organized collection.
  • Key:
  • Strong Points
  • Weak Points
  • Ratings:
  • Excellent
  • Very Good
  • Good

*The opinions expressed are solely those of the author(s) and should not be construed as reflecting the viewpoints of the publisher, Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., the publishing house, or employees and affiliates thereof.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »